Please click here to get more information. (Symbol: 6541)

• Jan. 16, 2019 Tanvex submits NDS for TX01 to Health Canada
• Dec. 06, 2018 Tanvex BioPharma Attends ASHP
• Nov. 28, 2018 FDA Accepts TX01 BLA Filing
• Oct. 01, 2018 Tanvex BioPharma Submits its First Biologics License Application to U.S. FDA For TX-01
• Sep. 19, 2018 Tanvex BioPharma to present at the YuanTa Biotech Investment Forum Asia 2018
• Sep. 05, 2018 Public offering of common stock completed
• Aug. 14, 2018 Tanvex Biologics Corporation (Taiwan) to expand process development capability
• Jul. 26, 2018 Tanvex BioPharma USA, Inc. signed agreement in Japan
• Jul. 04, 2018 Tanvex BioPharma announces proposed public offering of common stock
• May. 17, 2018 Tanvex Has Been Added to the MSCI Global Small Cap Index
• Mar. 20, 2018 Tanvex BioPharma to present at the 2018 BIO Asia International Conference
• Mar. 12, 2018 Tanvex BioPharma to present at the 30 th Annual ROTH Conference
• Mar. 1, 2018 Tanvex Name Change
• Jan 17, 2018 Tanvex BioPharma, Inc. held road show presentation
• Dec 19, 2017 TX16 Completed PK Study
• Oct 26, 2017 Tanvex BioPharma, Inc. got IPO in Taiwan
• Sep 28, 2017 TX05 Press Release
• Aug 24, 2017 TX01 Press Release
• July 20, 2017 Tanvex BioPharma, Inc. held road show presentation on July 20, 2017
• November 30, 2016 Tanvex BioPharma, Inc. has applied for primary listing on the Taiwan Stock Exchange.
• October 3, 2016 Tanvex BioPharma, Inc. Announces Initiation of Pivotal Trial of TX01 (a Proposed Biosimilar of Neupogen®)
• June 16, 2016 The 2016 Annual General Meeting of Tanvex Biopharma Inc. has passed several resolutions.
• June 14, 2016 Tanvex BioPharma, Inc. announced that the Board of Directors has approved to establish a new subsidiary in USA for its operational and business needs.
• March 28, 2016 Tanvex Biologics Corporation (Taiwan), a wholly owned subsidiary of Tanvex BioPharma, Inc. announced the result of its Board of Directors re-election.